  Novartis Vaccines (Basel, Switzerland, 

) plans  to produce approximately 40 million doses of its Fluvirin vaccine for  distribution in the US  during the upcoming 2007–2008 influenza season-a 30% increase in supply from  Novartis compared with the previous influenza season. Based on accelerated  production plans, approximately half of these doses are planned for delivery by  the end of September, with all doses expected to be delivered by the end of  October. 

Novartis has also formed a  strategic alliance with Intercell AG (Vienna,   Austria, 

) giving Novartis access  to 10 Intercell vaccine projects in preclinical early-stage development. Key  vaccine candidates included in the deal, valued at $270 million, are IC43 for  the prevention of hospital-acquired pseudomonas infections and IC47 for the prevention  of pneumonia infections. 

News

Novartis Vaccines (Basel, Switzerland, www.novartisvaccines.com) plans to produce approximately 40 million doses of its Fluvirin vaccine for distribution in the US during the upcoming 2007–2008 influenza season-a 30% increase in supply from Novartis compared with the previous influenza season.